Session » SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)
- 8:30AM-10:30AM
-
Abstract Number: 1273
A 12-week Aerobic Exercise Training Program in Women with Systemic Lupus Erythematosus (SLE) Improves Fatigue, Mitochondrial Dysfunction and Associated Interferon Gene Signature
- 8:30AM-10:30AM
-
Abstract Number: 1287
Association of Limited Health Literacy with Patient-Provider Communication in Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1259
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
- 8:30AM-10:30AM
-
Abstract Number: 1303
Associations Between Early Changes in Circulating B Cell Subsets and Severe Flare in Systemic Lupus Erythematosus – Results from Three Phase III Trials of Belimumab
- 8:30AM-10:30AM
-
Abstract Number: 1295
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
- 8:30AM-10:30AM
-
Abstract Number: 1272
Characterizing Patient and Physician Perceptions of Systemic Lupus Erythematosus (SLE) Disease Burden Using Traditional Rheumatoid Arthritis Outcomes Measures
- 8:30AM-10:30AM
-
Abstract Number: 1282
Classification of Disease Activity and Damage in Cutaneous Lupus
- 8:30AM-10:30AM
-
Abstract Number: 1298
Clinical Characteristics of Patients with Pre-pubertal Onset SLE and Disease Outcome Throughout Puberty: A Multicenter North American Longitudinal Study
- 8:30AM-10:30AM
-
Abstract Number: 1278
Clinical Outcomes in a Cohort of Puerto Ricans with Systemic Lupus Erythematosus After SARS CoV-2 Infection
- 8:30AM-10:30AM
-
Abstract Number: 1275
Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
- 8:30AM-10:30AM
-
Abstract Number: 1270
Disease Severity and Healthcare Costs Associated with Chronic Kidney Disease in Patients with Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1301
Early Increase in Circulating Memory B Cells Portends Clinical Response to Treatment in Pooled Data from Three Phase III Trials of Belimumab
- 8:30AM-10:30AM
-
Abstract Number: 1300
Effect of Time in Clinical Remission on Damage Accrual in Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1297
Factors Associated with Employment and Work Disability in Patients with SLE: A Nested Case-control Study
- 8:30AM-10:30AM
-
Abstract Number: 1260
Factors That Impact Medication Adherence in Hospitalized Patients with Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1288
First Year Infection Risk in SLE Patients Treated with Rituximab versus Standard of Care Treatment: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
- 8:30AM-10:30AM
-
Abstract Number: 1262
Fish Oil Supplementation and Pro-inflammatory and Pro-Resolving Lipid Mediators in Patients with and Without Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1267
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
- 8:30AM-10:30AM
-
Abstract Number: 1280
Generation of Evidence Supporting the Content Validity of SF-36, Lupus-Qol, and FACIT-Fatigue, and Newly Developed Patient-reported Outcome (PRO) Symptom Items to Address Conceptual Gaps for Use in Patient with Lupus Nephritis
- 8:30AM-10:30AM
-
Abstract Number: 1271
Healthcare Resource Utilization and Costs Associated with Systemic Lupus Erythematosus After Diagnosis of End-Stage Kidney Disease: Evidence from Two United States Databases
- 8:30AM-10:30AM
-
Abstract Number: 1279
Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort
- 8:30AM-10:30AM
-
Abstract Number: 1257
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1281
Longitudinal Association of Baseline Frailty with Patient-Reported Outcome Measures
- 8:30AM-10:30AM
-
Abstract Number: 1299
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
- 8:30AM-10:30AM
-
Abstract Number: 1285
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
- 8:30AM-10:30AM
-
Abstract Number: 1258
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
- 8:30AM-10:30AM
-
Abstract Number: 1296
Mortality and Survival in Argentinian Lupus Patients: A Multicenter Study
- 8:30AM-10:30AM
-
Abstract Number: 1284
One Third of Lupus Nephritis Patients Classified as Complete Responders Continue to Accrue Progressive Renal Damage Despite Resolution of Proteinuria
- 8:30AM-10:30AM
-
Abstract Number: 1265
Paradoxical Effect of Vitamin D on Bone Mineral Density in SLE
- 8:30AM-10:30AM
-
Abstract Number: 1277
Patient Perspectives on Two Distinct Patterns of Type 2 SLE Symptoms
- 8:30AM-10:30AM
-
Abstract Number: 1289
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
- 8:30AM-10:30AM
-
Abstract Number: 1268
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
- 8:30AM-10:30AM
-
Abstract Number: 1294
Predictors of BILAG-based Outcomes in Patients with SLE: Analysis from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort and MASTERPLANS Consortium
- 8:30AM-10:30AM
-
Abstract Number: 1276
Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
- 8:30AM-10:30AM
-
Abstract Number: 1266
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1264
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
- 8:30AM-10:30AM
-
Abstract Number: 1283
Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies
- 8:30AM-10:30AM
-
Abstract Number: 1291
Risk of Bleeding-related Complications After Kidney Biopsy in Patients with Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1274
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
- 8:30AM-10:30AM
-
Abstract Number: 1293
Studying Clusters of Patients with SLE According to Cognitive Function, Self-reported Outcomes, Disease Activity, and Clusters Dynamic over 1 Year
- 8:30AM-10:30AM
-
Abstract Number: 1292
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
- 8:30AM-10:30AM
-
Abstract Number: 1269
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
- 8:30AM-10:30AM
-
Abstract Number: 1261
The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
- 8:30AM-10:30AM
-
Abstract Number: 1263
Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
- 8:30AM-10:30AM
-
Abstract Number: 1286
Twenty-Year Trends in Systemic Lupus Erythematosus All–Cause Mortality in Mexico: A Nationwide Health Registry
- 8:30AM-10:30AM
-
Abstract Number: 1290
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials